Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10711167 | 1.00 | TSHR (0.58) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL20196494 | 1.00 | TSHR (0.58) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL1476186 | 1.00 | TSHR (0.58) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL17932915 | 1.00 | TSHR (0.58) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL10709681 | 1.00 | TSHR (0.58) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL6267245 | 1.00 | TSHR (0.58) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL155729 | 0.98 | TSHR (0.61) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL24773460 | 0.94 | L3MBTL1 (0.53) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL24773086 | 0.94 | L3MBTL1 (0.53) | TSHRNAAATDP1L3MBTL1IDO1 | |
| SCHEMBL13909725 | 0.94 | L3MBTL1 (0.57) | TSHRNAAATDP1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005102976-A1 | PROCESS FOR PREPARING NONAETHYLENE GLYCOL MONOMETHYL ETHER | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-03 | — | — | WO | claimed |
| US-7217409-B2 | Alkanoic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| US-7002012-B2 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2005102976-A1 | PROCESS FOR PREPARING NONAETHYLENE GLYCOL MONOMETHYL ETHER | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-0970081-B1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LTD (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20040067202-A1 | Novel alkanoic acid derivaties | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | US | disclosed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-20030181471-A1 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | DALUGE SUSAN MARY (US) | 2003-09-25 | — | — | US | disclosed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| EP-1318973-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | disclosed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
| US-6437124-B1 | XANTHINE DERIVATIVES WHICH INHIBIT EXPRESSION OF ADHESION MOLECULES ON HUMAN UMBILICAL VEIN ENDOTHELIAL CELL (HUVEC) MONOLAYERS AT VERY LOW CONCENTRATIONS | SMITHKLINE BEECHAM CORPORATION | 2002-08-20 | — | — | US | disclosed |
| WO-2002024623-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
| US-6355646-B1 | IMMUNOLOGY TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS SEPTIC SHOCK | GLAXO WELLCOME INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| EP-0970081-A1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035966-A1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067202-A1 | Novel alkanoic acid derivaties | ALK, FFAR1, FFAR3 | TSHR 2123/4885NAAA 1409/4885TDP1 1967/4885 |
| US-20030181471-A1 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | NOD1, PURB, NOD2 | TSHR 4663/4885NAAA 3756/4885TDP1 1764/4885 |
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | TSHR 3131/4885NAAA 736/4885TDP1 2690/4885 |
| US-20030032804-A1 | Methods of treating periodontal disease | HPGDS, SELP, ALPI | TSHR 3123/4885NAAA 3266/4885TDP1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.